The prevalence of joint ill in calves of crossbred dairy cattle was about 2.47% during study period of February to July 2016 (Table 2), which is lower than the reported prevalence of Wudu et al. (2008) which was 6% in Ethiopia. It might be due to geographical differences. Joint ill was more prevalent (3.31%) during May to July than that of February to April (0.98%) (Table 2). According to this study, the occurrence of joint ill was higher in female calves (57.14%) than male calves (42.86%) (Table 3), which is supported by the research findings of Goodarzi et al. (2015). The calves having 75% Holstein Friesian (HF) blood were more (71.43%) prone to joint ill in compare with calves having 62.5% Holstein Friesian (HF) blood (28.57%) (Table 3). The mortality of calves infected with joint ill was about 57.14% (Table 3). Mortality was insignificantly (P>0.05) higher in male (66.67%) than in female (50%) (Table 3). Again, mortality due to join ill was more in calves having 75% HF blood (60%) in compare with calves having 62.5% HF blood (50%) (Table 3), but the difference was not statistically significant (P>0.05).
Table 2: Prevalence of different diseases according to different month categories
%, Percentage; URT, Upper respiratory tract infection
Table 3: Overall statistics of joint ill infected calves
%, Percentage; SL, Shahiwal; HF, Holstein Friesian; SP, Streptomycin and penicillin; KCND, Kanamycin, Colistin Sulfate, Neomycin and Dexamethasone; N/D, Not Done
About 57.14% joint ill infected calves were subjected to treatment with SP followed by KCND while about 42.86 % were subjected to treatment with SP only. The treatment with SP followed by KCND was more efficient (75%) in compare with treatment with SP only (0%) (Table 3). The difference of fate of animal between two treatment groups was statistically significant (P<0.05). The isolated organisms from the joint fluid sample were E. coli and Staphylococcus sp. The result coincides with the results found in a research conducted by Nuss (2012). E. coli were sensitive to Tetracycline and Doxycycline and fully resistant to Amphicillin, Nalidixic acid, Chloramphenicol and Cholistin Sulfate (Table 4) which support the research findings of Paul et al. (2010). Staphylococcus sp., isolates showed distinctly sensitivity to Tetracycline and Doxycycline, moderately sensitive to Neomycin and resistance to Nalidixic acid, Chloramphenicol, Cholistin sulphate and Streptomycin (Table 4). Recent study findings partially support the previous research findings of Pereira and Siqueira-Jr (1995). The difference might be due to geographical differences or species variation of organism.
Table 4: Results of CS-test for E. coli and Staphylococcus sp. isolates
AMP, Ampicillin; S, Streptomycin; N, Neomycin; TE, Tetracycline; DO, Doxycycline; NA, Nalidixic acid; C, Chloramphenicol; CT, Colistin sulphate; S*, Sensitive; I, Intermediate sensitive; R, Resistant